Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.

Abstract

BACKGROUND & AIMS We evaluated the combination of daclatasvir (pan-genotypic NS5A inhibitor) and simeprevir (NS3/4A protease inhibitor), with or without ribavirin, in hepatitis C virus genotype 1-infected patients. METHODS This phase II, open-label study enrolled treatment-naive patients or prior null responders with genotype 1b (n=147) or 1a (n=21… (More)
DOI: 10.1016/j.jhep.2015.09.024

Topics

4 Figures and Tables

Cite this paper

@article{Zeuzem2016DaclatasvirPS, title={Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.}, author={Stefan Zeuzem and Christophe H{\'e}zode and J P Bronowicki and Veronique Loustaud-Ratti and F. Guti{\'e}rrez Gea and Mar{\'i}a Asunci{\'o}n But{\'i} and Antonio Olveira and Tivadar B{\'a}nyai and Mohammed T Al-Assi and J{\"{o}rg Petersen and Dominique Thabut and Adri{\'a}n Carlos Gadano and Ronald Pruitt and Mih{\'a}ly Makara and Marc Bourli{\'e}re and Stanislas Pol and Maria Beumont-Mauviel and Sivi Ouwerkerk-Mahadevan and Gaston Picchio and Marc Bifano and Fiona Mcphee and Navdeep Boparai and Kin Fai Cheung and Eric A. Hughes and Stephanie S. Noviello}, journal={Journal of hepatology}, year={2016}, volume={64 2}, pages={292-300} }